Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers.
about
Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.Non invasive tools for the diagnosis of liver cirrhosis.Non-invasive assessment of liver fibrosis in chronic hepatitis B.Liver elastography, comments on EFSUMB elastography guidelines 2013.Non-invasive assessment of liver fibrosis in chronic hepatitis C.A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.Impact of contacting study authors to obtain additional data for systematic reviews: diagnostic accuracy studies for hepatic fibrosis.A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosisSequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis BNon invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy.Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.Serum NX-DCP as a New Noninvasive Model to Predict Significant Liver Fibrosis in Chronic Hepatitis C.Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence.Validation of P2/MS for reflecting hepatic fibrosis in patients with hepatocellular carcinomaNoninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection.Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.A novel non-invasive index using AFP and APTT is associated with liver fibrosis in patients with chronic hepatitis B infection: a retrospective cohort studyDevelopment of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms.A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C.Assessing liver fibrosis.Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis.Look-back screening for the identification of transfusion-induced hepatitis C virus infection in Sweden.Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations.Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis.Development and evaluation of a novel score for prediction of large oesophageal varices in patients with hepatitis c virus-induced liver cirrhosis.Fibro markers for prediction of hepatocellular carcinoma in Egyptian patients with chronic liver disease.Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B.The prognostic values of 12 cirrhosis-relative noninvasive models in patients with hepatocellular carcinoma.Hepatoprotective effect of juglone on dimethylnitrosamine-induced liver fibrosis and its effect on hepatic antioxidant defence and the expression levels of α-SMA and collagen III.In vivo evaluation of ethanolic extract of Zingiber officinale rhizomes for its protective effect against liver cirrhosis.Chronic hepatitis C in Swedish subjects receiving opiate substitution therapy--factors associated with advanced fibrosis.Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse.A model to predict antiviral treatment in HBeAg negative chronic hepatitis B with alanine aminotransferase≤2 upper limit of normal.Non-invasive assessment of liver fibrosis.A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection.The diagnostic value of non-invasive tests for the evaluation of liver fibrosis in chronic hepatitis B patients.Usefulness of six non-proprietary indirect markers of liver fibrosis in patients with chronic hepatitis C.PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C.Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease.Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study.
P2860
Q30362068-D26FF21F-B159-4BB8-A2E9-B5991A80C6BBQ30421450-2DAABA3B-2DBD-45C3-BAB8-2E8D33645BBEQ30427489-8FD898D8-8256-49FC-8659-E91F74031B81Q30448132-8EE6EBA5-9A08-4394-8028-C289E5F0870FQ30474738-0E5391B2-D03C-4451-A02B-6FE3564B43BEQ30476922-658D59A3-0F75-40A8-B8EF-ABE8681AE643Q30853941-6545EEB0-3A5A-4580-A031-39E9F6FC05D5Q31157282-F2A6F53F-3B50-4623-B3BF-73EB7A5F3180Q33787916-C87B3805-446D-400E-8A3C-80B39FBE740EQ33866383-C12D0DF8-82DB-4BF0-A068-4A4ABB9196FAQ34812618-18A5184D-4B90-4970-9EC4-783CC27D83DAQ35149315-EBC37078-6989-490E-A756-86E9929EB1DFQ35594262-5495FB39-12DE-482A-9541-C16978D534ABQ35833021-F87B9728-ED98-4915-ACC0-7E75031FFDC1Q36049926-5AC7B159-4DBE-4070-A19B-05230E55CECAQ36052963-4AAB7653-EAF9-4B39-9D6D-866F6EC87843Q36080925-B420BA3B-0989-483F-AFCA-9F7A91719353Q36218142-DFE4062F-B36F-486E-BD94-159D468D867FQ37090659-23CA526D-24EF-4EF4-BD8F-99F8A287AD7BQ37345958-50D959EA-54E1-4EB0-AE94-D59B07A7A938Q37841383-5BEE8085-5CC6-432A-A544-482A7D5758A7Q37849760-078991D9-EB3F-461A-BAD8-A02AACD58879Q38002889-20EAB0C1-F7E6-4D67-916F-9A5047C06D20Q38540088-D54FC023-2453-4654-B0E4-FD1C844926C3Q38999576-FB8FC607-E6AB-48EC-B70E-C6367139D5F0Q39256947-F715B9AB-118F-466A-BDFC-A1FE6AC96149Q40707349-0B353982-7260-44BE-A5BD-4EFD5DB9BB20Q41736718-6C6EED9D-5DC4-43AF-857E-15BECF35A3F2Q42017535-E7B864F9-3AD1-415D-8CD3-68E8CD6A96C0Q42019432-8DF9B73C-97F2-443F-A2E7-02B02A7FC02EQ42227752-14D0B77C-AE37-4D61-BE5E-EAA6DB1F306CQ42257750-F4E5607D-EB57-442A-B02E-54EC4E42C7A4Q42263583-02BB1DCB-DF4C-4F34-90AD-80C86B681513Q42406716-C86F274A-00CB-49D6-9637-67D5974AB032Q45389693-8E43460C-C302-4079-8EA5-FD1764541D89Q46485907-99D8F0BC-C481-4520-8268-F319C4F20275Q46715188-C05F538D-26C9-42E1-9431-5041C132AD67Q47600533-61F8B7C3-0E5E-4561-8753-1D94FFC04903Q47802250-F5A62223-E094-468F-BF27-8FC14699AB0AQ50041788-E31E8D8C-2740-4866-8CFD-CAC11E47BF0D
P2860
Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Cirrhosis in hepatitis C virus ...... ard biochemical serum markers.
@en
Cirrhosis in hepatitis C virus ...... ard biochemical serum markers.
@nl
type
label
Cirrhosis in hepatitis C virus ...... ard biochemical serum markers.
@en
Cirrhosis in hepatitis C virus ...... ard biochemical serum markers.
@nl
prefLabel
Cirrhosis in hepatitis C virus ...... ard biochemical serum markers.
@en
Cirrhosis in hepatitis C virus ...... ard biochemical serum markers.
@nl
P2093
P2860
P1476
Cirrhosis in hepatitis C virus ...... ard biochemical serum markers.
@en
P2093
Johan Westin
Linda Antonsson
Sara Islam
P2860
P304
P356
10.1080/00365520510015674
P577
2005-07-01T00:00:00Z